Company Filing History:
2 out of 76 
1 out of 454 
1 out of 60 
Years Active: 1996-2003
Title: The Innovative Contributions of Peter Lind
Introduction
Peter Lind is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of pharmaceutical compositions and antibodies. With a total of 5 patents, his work has the potential to impact the treatment of various cardiovascular diseases.
Latest Patents
One of Peter Lind's latest patents is focused on the dimer of a molecular variant of apolipoprotein. This invention involves the isolation and characterization of substantially pure dimers of Apolipoprotein AI-Milano from plasma. The dimer can be produced in a recombinant system and is described as having therapeutic applications for patients suffering from atherosclerosis or cardiovascular diseases. Additionally, it can be used to prevent thrombosis in various clinical situations. Another significant patent involves antibodies that bind to the monocyte chemoattractant protein 1 receptor, CCR2. These antibodies can function as either agonists or antagonists and have applications in diagnostics, drug screening, and therapeutic use.
Career Highlights
Throughout his career, Peter Lind has worked with prominent companies such as Pharmacia & Upjohn and the Spanish National Research Council. His experience in these organizations has contributed to his expertise in the field of biotechnology and pharmaceuticals.
Collaborations
Peter Lind has collaborated with esteemed colleagues, including Cesare Sirtori and Guido Franceschini. These partnerships have likely enhanced his research and development efforts, leading to innovative solutions in the medical field.
Conclusion
Peter Lind's contributions to biotechnology and pharmaceuticals are noteworthy, with his patents paving the way for advancements in the treatment of cardiovascular diseases. His work exemplifies the impact of innovation in improving healthcare outcomes.